Maximal level of SRC inhibition in patient samples after a single dose of NXP900 exceeded 90%. Three preclinical posters highlight potential use of NXP900 in NSCLC As a single agent, NXP900 ...

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on the company’s ...

KalVista Pharmaceuticals, Inc. today announced that it will present new sebetralstat data at two upcoming congresses taking place concurrently from May 29?June 1, 2025: the 14th C1-inhibitor ...

("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in ...

Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology responseData contribute to growing body of support around the anti-fibrotic ...

REVEAL GENOMICS, S.L., a biotechnology company advancing precision oncology through biomarker innovation, today announced the presentation of four independent studies at the 2025 ASCO Annual Meeting.

At the 28th annual Undergraduate Research Symposium, more than 1,500 undergraduate students from UW and partnering ...

ADC Therapeutics SA (NYSE: ADCT) Q1 2025 Earnings Call Transcript May 14, 2025 ADC Therapeutics SA beats earnings ...

Detailed price information for Monopar Therapeutics Inc (MNPR-Q) from The Globe and Mail including charting and trades.

Premeds can get an edge by being published several ways, from hypothesis-based research papers to conference abstracts.

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online ...

Q1 2025 Earnings Call Transcript May 12, 2025 Xenon Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.83, ...